These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 34315295)

  • 1. Rituximab use in pediatric systemic lupus erythematosus: Indications, efficacy and safety in an Indian cohort.
    Sawhney S; Agarwal M
    Lupus; 2021 Oct; 30(11):1829-1836. PubMed ID: 34315295
    [No Abstract]   [Full Text] [Related]  

  • 2. Effectiveness and Safety of Rituximab in Systemic Lupus Erythematosus: A Case Series Describing the Experience of 2 Centers.
    Gómez VJ; Carrión-Barberá I; Salman Monte TC; Acosta A; Torrente-Segarra V; Monfort J
    Reumatol Clin (Engl Ed); 2020; 16(5 Pt 2):391-395. PubMed ID: 30522941
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Rituximab therapy for severe pediatric systemic lupus erythematosus].
    Su GX; Wu FQ; Wang F; Zhou ZX; Huang XL; Lu J
    Zhonghua Er Ke Za Zhi; 2012 Sep; 50(9):697-704. PubMed ID: 23158822
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The retrospective evaluation of efficacy and safety data after switching from originator rituximab to biosimilar rituximab (CT-P10) in patients diagnosed with systemic lupus erythematosus: a single-center experience.
    Ekin A; Mısırcı S; Coşkun BN; Yağız B; Dalkılıç E; Pehlivan Y
    Eur Rev Med Pharmacol Sci; 2024 May; 28(10):3513-3522. PubMed ID: 38856126
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rituximab as add-on therapy in patients with resistant lupus nephritis who have failed induction or maintenance therapy with other agents: A real-world experience from a single center in Mumbai.
    Yadav S; Balakrishnan C; Mangat G; Kothari J
    Lupus; 2024 Jan; 33(1):88-95. PubMed ID: 38048588
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and efficacy of rituximab in childhood-onset systemic lupus erythematosus and other rheumatic diseases.
    Tambralli A; Beukelman T; Cron RQ; Stoll ML
    J Rheumatol; 2015 Mar; 42(3):541-6. PubMed ID: 25593242
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anti CD20 (Rituximab) therapy in refractory pediatric rheumatic diseases.
    Reis J; Aguiar F; Brito I
    Acta Reumatol Port; 2016; 41(1):45-55. PubMed ID: 27115107
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and Safety of Rituximab in the Management of Pediatric Systemic Lupus Erythematosus: A Systematic Review.
    Mahmoud I; Jellouli M; Boukhris I; Charfi R; Ben Tekaya A; Saidane O; Ferjani M; Hammi Y; Trabelsi S; Khalfallah N; Tekaya R; Gargah T; Abdelmoula L
    J Pediatr; 2017 Aug; 187():213-219.e2. PubMed ID: 28602379
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and Safety of Rituximab in Systemic Lupus Erythematosus and Sjögren Syndrome Patients With Refractory Thrombocytopenia: A Retrospective Study of 21 Cases.
    Jiang B; Li T; Guo L; Shen H; Ye S; Chen S
    J Clin Rheumatol; 2015 Aug; 21(5):244-50. PubMed ID: 26203828
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Differences in rituximab use between pediatric rheumatologists and nephrologists for the treatment of refractory lupus nephritis and renal flare in childhood-onset SLE.
    Gilbert M; Goilav B; Hsu JJ; Nietert PJ; Meidan E; Chua A; Ardoin SP; Wenderfer SE; von Scheven E; Ruth NM;
    Pediatr Rheumatol Online J; 2021 Aug; 19(1):137. PubMed ID: 34461932
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rituximab as Maintenance Treatment for Systemic Lupus Erythematosus: A Multicenter Observational Study of 147 Patients.
    Cassia MA; Alberici F; Jones RB; Smith RM; Casazza G; Urban ML; Emmi G; Moroni G; Sinico RA; Messa P; Hall F; Vaglio A; Gallieni M; Jayne DR
    Arthritis Rheumatol; 2019 Oct; 71(10):1670-1680. PubMed ID: 31102498
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and efficacy of rituximab in refractory pediatric systemic lupus erythematosus nephritis: a single-center experience of Northern Greece.
    Trachana M; Koutsonikoli A; Farmaki E; Printza N; Tzimouli V; Papachristou F
    Rheumatol Int; 2013 Mar; 33(3):809-13. PubMed ID: 22101555
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rituximab therapy for juvenile-onset systemic lupus erythematosus.
    Nwobi O; Abitbol CL; Chandar J; Seeherunvong W; Zilleruelo G
    Pediatr Nephrol; 2008 Mar; 23(3):413-9. PubMed ID: 18097688
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of rituximab for systemic lupus erythematosus-associated immune cytopenias: A multicenter retrospective cohort study of 71 adults.
    Serris A; Amoura Z; Canouï-Poitrine F; Terrier B; Hachulla E; Costedoat-Chalumeau N; Papo T; Lambotte O; Saadoun D; Hié M; Blanche P; Lioger B; Gottenberg JE; Godeau B; Michel M
    Am J Hematol; 2018 Mar; 93(3):424-429. PubMed ID: 29247540
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of rituximab in childhood-onset, difficult-to-treat nephrotic syndrome: A multicenter open-label trial in Korea.
    Ahn YH; Kim SH; Han KH; Choi HJ; Cho H; Lee JW; Shin JI; Cho MH; Lee JH; Park YS; Ha IS; Cheong HI; Kim SY; Lee SJ; Kang HG
    Medicine (Baltimore); 2018 Nov; 97(46):e13157. PubMed ID: 30431588
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of rituximab in Japanese patients with systemic lupus erythematosus and lupus nephritis who are refractory to conventional therapy.
    Tanaka Y; Takeuchi T; Miyasaka N; Sumida T; Mimori T; Koike T; Endo K; Mashino N; Yamamoto K
    Mod Rheumatol; 2016; 26(1):80-6. PubMed ID: 26054418
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Use of Rituximab in Systemic Lupus Erythematosus: A Single Center Experience Over 14 Years.
    Aguiar R; Araújo C; Martins-Coelho G; Isenberg D
    Arthritis Care Res (Hoboken); 2017 Feb; 69(2):257-262. PubMed ID: 27110698
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and efficacy of rituximab in systemic lupus erythematosus: results from 136 patients from the French AutoImmunity and Rituximab registry.
    Terrier B; Amoura Z; Ravaud P; Hachulla E; Jouenne R; Combe B; Bonnet C; Cacoub P; Cantagrel A; de Bandt M; Fain O; Fautrel B; Gaudin P; Godeau B; Harlé JR; Hot A; Kahn JE; Lambotte O; Larroche C; Léone J; Meyer O; Pallot-Prades B; Pertuiset E; Quartier P; Schaerverbeke T; Sibilia J; Somogyi A; Soubrier M; Vignon E; Bader-Meunier B; Mariette X; Gottenberg JE;
    Arthritis Rheum; 2010 Aug; 62(8):2458-66. PubMed ID: 20506527
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of an anti-CD20 monoclonal antibody, rituximab, for lupus nephritis: A meta-analysis.
    Teng S; Tian Y; Luo N; Zheng Q; Shao M; Li L
    Int J Rheum Dis; 2022 Feb; 25(2):101-109. PubMed ID: 34811947
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rituximab use as induction therapy for lupus nephritis: a systematic review.
    Stolyar L; Lahita RG; Panush RS
    Lupus; 2020 Jul; 29(8):892-912. PubMed ID: 32486934
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.